241 related articles for article (PubMed ID: 22298804)
21. Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant.
Strasburger CJ; Mattsson A; Wilton P; Aydin F; Hey-Hadavi J; Biller BMK
Eur J Endocrinol; 2018 Apr; 178(4):321-329. PubMed ID: 29371335
[TBL] [Abstract][Full Text] [Related]
22. Pegvisomant: new preparation. A last resort in acromegaly.
Prescrire Int; 2005 Feb; 14(75):10-3. PubMed ID: 15751152
[TBL] [Abstract][Full Text] [Related]
23. Somatotroph tumor progression during pegvisomant therapy: a clinical and molecular study.
Marazuela M; Paniagua AE; Gahete MD; Lucas T; Alvarez-Escolá C; Manzanares R; Cameselle-Teijeiro J; Luque-Ramirez M; Luque RM; Fernandez-Rodriguez E; Castaño JP; Bernabeu I
J Clin Endocrinol Metab; 2011 Feb; 96(2):E251-9. PubMed ID: 21068147
[TBL] [Abstract][Full Text] [Related]
24. The effect of acute application of pegvisomant alone and in combination with octreotide on endogenous GH levels during a 6-h test in patients with acromegaly on constant pegvisomant treatment.
Roemmler J; Steffin B; Gutt B; Sievers C; Bidlingmaier M; Schopohl J
Growth Horm IGF Res; 2009 Jun; 19(3):245-51. PubMed ID: 19109045
[TBL] [Abstract][Full Text] [Related]
25. The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly.
Bernabeu I; Alvarez-Escolá C; Quinteiro C; Lucas T; Puig-Domingo M; Luque-Ramírez M; de Miguel-Novoa P; Fernandez-Rodriguez E; Halperin I; Loidi L; Casanueva FF; Marazuela M
J Clin Endocrinol Metab; 2010 Jan; 95(1):222-9. PubMed ID: 19850678
[TBL] [Abstract][Full Text] [Related]
26. Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY.
Freda PU; Gordon MB; Kelepouris N; Jonsson P; Koltowska-Haggstrom M; van der Lely AJ
Endocr Pract; 2015 Mar; 21(3):264-74. PubMed ID: 25370326
[TBL] [Abstract][Full Text] [Related]
27. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis.
Biering H; Saller B; Bauditz J; Pirlich M; Rudolph B; Johne A; Buchfelder M; Mann K; Droste M; Schreiber I; Lochs H; Strasburger CJ;
Eur J Endocrinol; 2006 Feb; 154(2):213-20. PubMed ID: 16452533
[TBL] [Abstract][Full Text] [Related]
28. Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs.
Herman-Bonert VS; Zib K; Scarlett JA; Melmed S
J Clin Endocrinol Metab; 2000 Aug; 85(8):2958-61. PubMed ID: 10946911
[TBL] [Abstract][Full Text] [Related]
29. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study.
Puig-Domingo M; Soto A; Venegas E; Vilchez R; Blanco C; Cordido F; Lucas T; Marazuela M; Casany R; Cuatrecasas G; Fajardo C; Gálvez MÁ; Maraver S; Martín T; Romero E; Paja M; Picó A; Bernabeu I; Resmini E;
Endocrinol Nutr; 2016 Oct; 63(8):397-408. PubMed ID: 27448708
[TBL] [Abstract][Full Text] [Related]
30. Three weeks on a high-fat diet increases intrahepatic lipid accumulation and decreases metabolic flexibility in healthy overweight men.
van Herpen NA; Schrauwen-Hinderling VB; Schaart G; Mensink RP; Schrauwen P
J Clin Endocrinol Metab; 2011 Apr; 96(4):E691-5. PubMed ID: 21252252
[TBL] [Abstract][Full Text] [Related]
31. The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment.
Roemmler J; Steffin B; Gutt B; Schneider HJ; Sievers C; Bidlingmaier M; Schopohl J
Growth Horm IGF Res; 2010 Oct; 20(5):338-44. PubMed ID: 20598600
[TBL] [Abstract][Full Text] [Related]
32. Combination treatment with somatostatin analogues and pegvisomant in acromegaly.
Neggers SJ; van der Lely AJ
Growth Horm IGF Res; 2011 Jun; 21(3):129-33. PubMed ID: 21498099
[TBL] [Abstract][Full Text] [Related]
33. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY.
van der Lely AJ; Biller BM; Brue T; Buchfelder M; Ghigo E; Gomez R; Hey-Hadavi J; Lundgren F; Rajicic N; Strasburger CJ; Webb SM; Koltowska-Häggström M
J Clin Endocrinol Metab; 2012 May; 97(5):1589-97. PubMed ID: 22362824
[TBL] [Abstract][Full Text] [Related]
34. The German ACROSTUDY: past and present.
Buchfelder M; Schlaffer S; Droste M; Mann K; Saller B; Brübach K; Stalla GK; Strasburger CJ;
Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S3-S10. PubMed ID: 19684061
[TBL] [Abstract][Full Text] [Related]
35. Growth Hormone and Insulin Signaling in Acromegaly: Impact of Surgery Versus Somatostatin Analog Treatment.
Dal J; Høyer KL; Pedersen SB; Magnusson NE; Bjerring P; Frystyk J; Møller N; Jessen N; Jørgensen JO
J Clin Endocrinol Metab; 2016 Oct; 101(10):3716-3723. PubMed ID: 27466699
[TBL] [Abstract][Full Text] [Related]
36. Pegvisomant: an advance in clinical efficacy in acromegaly.
Stewart PM
Eur J Endocrinol; 2003 Apr; 148 Suppl 2():S27-32. PubMed ID: 12670298
[TBL] [Abstract][Full Text] [Related]
37. Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly.
Auriemma RS; Grasso LF; Galdiero M; Galderisi M; Pivonello C; Simeoli C; De Martino MC; Ferrigno R; Negri M; de Angelis C; Pivonello R; Colao A
Endocrine; 2017 Mar; 55(3):872-884. PubMed ID: 27295183
[TBL] [Abstract][Full Text] [Related]
38. Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly.
Bianchi A; Mazziotti G; Tilaro L; Cimino V; Veltri F; Gaetani E; Pecorini G; Pontecorvi A; Giustina A; De Marinis L
Pituitary; 2009; 12(3):196-9. PubMed ID: 19089622
[TBL] [Abstract][Full Text] [Related]
39. [Optimization of the medical treatment for acromegaly].
Díez JJ; Iglesias P
Med Clin (Barc); 2013 Apr; 140(8):360-5. PubMed ID: 23103101
[TBL] [Abstract][Full Text] [Related]
40. Conversion of daily pegvisomant to weekly pegvisomant combined with long-acting somatostatin analogs, in controlled acromegaly patients.
Neggers SJ; de Herder WW; Feelders RA; van der Lely AJ
Pituitary; 2011 Sep; 14(3):253-8. PubMed ID: 21221818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]